Eight patients with pancreatic neoplasia were confirmed by surgery or fine-needle aspiration (10% yield of screening); of these, six patients had benign intraductal papillary mucinous neoplasms (IPMNs), one had an IPMN that progressed to invasive ductal adenocarcinoma, and one had a PanIN-1.
The Food and Drug Administration has approved Velcade to treat a type of cancer called multiple myeloma. Velcade should only be used in people who have already been treated with two other types of chemotherapy (drugs used to kill cancer cells), and whose cancer has still progressed on the most recent therapy.Velcade is a new type of cancer drug called a proteasome inhibitor.Proteasomes are enzymes found in cells, and play a role in regulating cell function and growth. Velcade blocks the activity of proteasomes. This blockade can lead to death of cancer cells.elcade is a new type of cancer drug called a proteasome inhibitor. Proteasomes are enzymes found in cells, and play a role in regulating cell function and growth. Velcade blocks the activity of proteasomes. This blockade can lead to death of cancer cells.
Bortezomib (Velcade Â®). Bortezomib, which is commonly known as VelcadeÂ®, is currently used to treat people with multiple myeloma | . Bortezomib may also be used to treat other types of cancer as part of a research trial. You'll see your doctor regularly while you have this treatment so they can monitor its effects.ou can have up to eight cycles of treatment over six months. When bortezomib is given in combination with melphalan and prednisone, itâs given over nine cycles of six weeks. During the first four cycles, the bortezomib is given twice a week.